BerGenBio taps into Piramal’s platform to develop leukemia treatment

By Vassia Barba

- Last updated on GMT

(Image: Getty/undefined)
(Image: Getty/undefined)

Related tags Piramal CDMO Leukemia Contract manufacturing

Piramal to support the development of BerGenBio’s treatment for acute myeloid leukemia, after the US FDA granted the candidate fast track designation.

BerGenBio’s bemcentinib is a selective AXL inhibitor, currently in Phase II clinical trials as a combination and single agent therapy for lung cancer and leukemia.  

The US Food and Drug Administration (FDA) recently granted the candidate fast track designation for the treatment of elderly patients with acute myeloid leukemia (AML) whose disease has relapsed, an indication for which there are no approved drugs available to date.

Following the designation, the drug developer announced its plans to outsource further development and manufacturing operations to Piramal, and the latter’s ‘Xcelerate Integrated Solutions’ platform, which, according to BerGenBio’s CEO, Richard Godfrey, represents an ‘ideal’ solution.

According to Piramal, this specific service was chosen in order to meet the timelines required for fast track development.

However, Piramal’s program includes a long manufacturing journey, with the required intermediates sourced in India; subsequently, the pilot process development and validation takes place in North America; and, ultimately, the formulation development will occur in Europe.

The Xcelerate program has been successfully applied to more than eighty programs to date, according to Piramal, with the company stating that it is preferable for clients due to its streamlined services, “managed by a single point of contact who expedites the exchange of information.”

Upon the potential regulatory approval of the candidate, Piramal will also provide the commercial manufacture of the final drug product.

Financial terms of the partnership were not disclosed.

Related news

Show more

Related products

show more

Drug Solubility and the Need for Speed

Drug Solubility and the Need for Speed

Lonza Small Molecules | 28-Mar-2023 | Technical / White Paper

A growing number of new chemical entities are highly insoluble, leading to problems with bioavailability. Drug manufacturers therefore have to find ways...

2023 State of Clinical Trial Technology Report

2023 State of Clinical Trial Technology Report

Florence Healthcare | 01-Mar-2023 | Insight Guide

Discover the trends shaping clinical trial technology in 2023, from Site Enablement to eISFs, integrations, and site-sponsor collaboration. This report...

Plan for success with process liquid and buffer preparation

Plan for success with process liquid and buffer preparation

Thermo Fisher Scientific - Process Liquid Preparation Services | 21-Feb-2023 | Technical / White Paper

Setting the groundwork for successful scale-up is essential for getting a therapeutic to market quickly and efficiently, but navigating the unknowns associated...

Related suppliers

Follow us


View more